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What is translational genomics? An expanded research agenda 
for improving individual and population health
Sheri D. Schully, Muin J. Khoury
The mission of Applied and Translational Genomics is “to enhance the knowledge, clinical 
adoption and discussion of applied and translational genomics worldwide” [1]. But, it is still 
unclear what is meant by the term translational genomics. There are varying definitions of 
translational research [2] that have been applied to genomic medicine [3] and other areas 
(e.g., cancer survivorship research [4]).
Here, we briefly describe our view definition of translational research in genomics as 
spanning the whole spectrum of scientific activities going beyond the traditional “bench 
to bedside” model [1] to a more expanded continuum that includes improvement in 
healthcare and disease prevention [5]. We have previously described this framework 
(described as T0-T4 research) [6,7]. Currently, there is a great amount of genomic 
discovery research occurring that includes new genomic variants, biomarkers and other basic 
science discoveries (T0). Beyond the initial discovery, there are 4 overlapping phases of 
translational genomic research (Fig. 1): T1 research, which bridges discovery to candidate 
health applications, or “bench to beside”. T1 research encompasses the development of 
new diagnostic tests or interventions in the clinical setting but in a limited fashion. An 
example of T1 research would be evaluating gene–environment interactions or evaluating 
the function of genomic variants. T2 research evaluates the clinical utility of candidate 
genomic applications in clinical practice. For example, this type of research would include 
whether a genomic application performs better than the standard of care in improving 
health outcomes or developing evidence from the clinical setting to informed evidence­
based guidelines. T3 research includes studies that assess implementation and integration 
of genomics into routine clinical practice. T3 research would include, for example, the 
evaluation of implementing genomic applications in community-based centers. T4 research 
evaluates population health impact of genomic medicine. An example of T4 research would 
be performing nationwide surveillance to evaluate how the implementation of a particular 
genomic test has affected population health.
Currently, there is very little genomics research conducted and published in T2-T4 research. 
For example, the NCI's Cancer Genomics and Epidemiology Navigator (CGEN http://
epi.grants.cancer.gov/cgen), an online freely accessible tool about resources and publications 
for cancer genomics and epidemiology research, indicates that there are over 22,500 cancer­
related genomic epidemiology (Human Genomic Epidemiology (HuGE)) publications. From 
the same database we see that there are currently 344 genomic applications that have 
been proposed for cancer care and prevention since 2009. In addition, there are only 
70 evidence-based recommendations that address cancer-based genomic test. Only 26 are 
recommended for use of the application in a health care setting by professional groups 
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or guideline developers (tier 1 applications). The vast majority have insufficient evidence 
base or negative recommendation for use. Additionally, groups such as the Office of Public 
Health Genomics at the Centers for Disease Control and Prevention have made an attempt 
to categorize genomic applications in terms of the level of synthesized evidence for their use 
in a clinical setting [8] to help guide researchers, policy makers and practitioners. This is the 
same trend that we see over and over again in the field of genomics. There are thousands 
of studies that show promising genomic discoveries that lead to promising interventions. 
However, only a few of these interventions “stick” and make an impact on healthcare. 
Schully et al. [7,9] as well as Clyne [10] found that less than 2% of cancer genomics 
research funded by the National Cancer Institute and less than 0.5% of published cancer 
genomics research is T2 and beyond. Additionally, a recent analysis of the National Heart 
Lung and Blood Institute's genomics portfolio shows a similar trend [10]. Implementation 
of genomic applications that lack an evidence base can have high costs in terms of adverse 
health outcomes and increased health care costs.
Since it is unlikely that randomized clinical trials (RCTs) will be performed on every 
promising genomic application, researchers must strive to gain an evidence base for 
these applications by conducting appropriate observational studies [11] and comparative 
effectiveness research [12].
Once a promising intervention is identified in genomics, critical research is needed in 
order to determine if the application should be recommended for routine use in a health 
care setting. Behavioral and communication research also are needed to determine patterns 
of utilization and patient communication. Comparative effectiveness research (CER) also 
is needed to determine the clinical validity and utility of the applications, in comparison 
with existing practice. Additionally, health services and implementation research can track 
integration of tests in practice and measure disparities in access [13]. Additionally, multi­
level research should also be performed to evaluate how an individual's external environment 
(family dynamics, neighborhood factors, state and federal policies, etc.) affects the overall 
outcomes of the genomic application [14].
If we continue to perform T0-T1 research without also addressing behavioral, CER, 
implementation, utilization, surveillance, and multi-level research, the promise of genomic 
medicine for improving health and preventing disease will not be fulfilled. All phases of 
translation research, especially T2+ research are integral to making a population health 
impact.
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